You are here: Industry Insights > non-small cell lung cancer

News List

University of Liverpool to Use Touchlight’s Rapid Enzymatic dbDNA in Fully Personalised Neoantigen Cancer Vaccine Clinical Study PharmaSources
April 07, 2024
Touchlight announced an agreement with University of Liverpool for the use of dbDNA in the development of a fully-personalised therapeuticneoantigen DNA vaccine for patients with non-small cell lung cancer.
QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC) firstwordpharma
May 26, 2021
QIAGEN N.V. today announced MRTX to continue developing a tissue-based KRAS companion diagnostic to identify patients with cancers that have a KRASG12C mutation from treatment with adagrasib, Mirati's investigational
FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer fda.gov
May 24, 2021
Today, the U.S. Food and Drug Administration approved Rybrevant as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: EGFR exon 20 insertion mutations.
Hansoh Pharma's Ameile (Almonertinib) Receives Marketing Authorization in China for Second-Line Treatment for Patients With EGFR T790M-Mutation Non-Small Cell Lung Cancer prnasia
March 19, 2020
AMEILE is the second 3rd generation EGFR TKI to be approved for metastatic NSCLC patients with EGFR T790M.
EC approves Merck’s Keytruda for metastatic squamous NSCLC pjavascript:void('body')harmaceutical-technology
March 19, 2019
Micrograph showing a non-small cell lung carcinoma. Credit: Librepath.The European Commission (EC) has approved Merck’s anti-PD-1 therapy Keytruda as a first-line treatment for adults with metastatic squamous non-small cell lung cancer (NSCLC).